Back in 2021, Amgen picked up the phase 3-ready candidate in a $1.9 billion acquisition of Five Prime Therapeutics. The ...

Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab in combination with ...

FGFR2b overexpression was defined as 2+/3+ staining in ≥10% of tumor cells by centrally performed immunohistochemistry (IHC) testing. Gastric cancer is the fifth leading cause of cancer-related death ...

Amgen acquired Five Prime in 2021 on the back of the phase 2 FIGHT trial of bemarituzumab, which achieved significant ...

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.

Amgen said on Monday its experimental cancer therapy significantly improved overall survival in patients with advanced ...

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

US biotech major Amgen today announced the Phase III FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus ...

Amgen & Zai Lab's trial shows bemarituzumab + chemo boosts survival in gastric cancer with FGFR2b. Read more here.

In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though ...

FIGHT enrolled 153 patients with FGFR2b-positive, HER2-negative gastric tumours, and compared Five Prime’s antibody to the mFOLFOX6 chemotherapy regimen, a standard treatment for this type of ...